A German court on Friday ruled that Eli Lilly & Co. cannot prevent a competitor from selling a generic form of its key Alimta cancer drug once the patent expires this December.
A German court on Friday ruled that Eli Lilly & Co. cannot prevent a competitor from selling a generic form of its key Alimta cancer drug once the patent expires this December.